Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback